Sonoma Pharmaceuticals (SNOA) Income from Discontinued Operations (2016 - 2021)

Sonoma Pharmaceuticals' Income from Discontinued Operations history runs 4 years deep, the most recent figure standing at 228000.0 for Q1 2021.

• On a quarterly basis, Income from Discontinued Operations rose 147.83% year-over-year to 228000.0 in Q1 2021; TTM through Sep 2021 was 228000.0, a 147.83% increase from a year earlier, with the FY2021 full-year figure at 228000.0, up 147.83% from the prior year.
• Income from Discontinued Operations advanced to 228000.0 in Q1 2021 per SNOA's latest filing, from 92000.0 in the prior quarter.
• Across five years, Income from Discontinued Operations topped out at 228000.0 in Q1 2021 and bottomed at 301000.0 in Q1 2017.
• The 3-year median for Income from Discontinued Operations is 92000.0 (2020), against an average of 6333.33.
• Biggest YoY gain for Income from Discontinued Operations was 147.83% in 2021; the steepest drop was 147.83% in 2021.
• Year by year, Income from Discontinued Operations stood at 301000.0 in 2017, then soared by 130.56% to 92000.0 in 2020, then jumped by 147.83% to 228000.0 in 2021.
• Per Business Quant, the three latest SNOA Income from Discontinued Operations figures stand at 228000.0 (Q1 2021), 92000.0 (Q1 2020), and 301000.0 (Q1 2017).